Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
EBAG9
REST API REST API
Homo sapiens
EBAG9 is differentially expressed in 283 experiments: 108 organism parts: bone marrow, heart, ... (106 more);, 175 disease states: normal, control, ... (173 more);, 80 cell types 420 cell lines 43 compound treatments and 73 other conditions.
Synonyms EB9, RCAS1
Orthologs ebag9 (Danio rerio)   Ebag9 (Mus musculus)   Ebag9 (Rattus norvegicus)   D3ZWS7_RAT (Rattus norvegicus)   Q0P578_BOVIN (Bos taurus)   ebag9 (Xenopus laevis)   RCAS1_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term focal adhesion, plasma membrane, apoptosis, apoptotic protease activator activity, Golgi membrane, Golgi apparatus, soluble fraction, regulation of cell growth, integral to membrane
InterPro Term Cancer-assoc_antigen_RCAS1
UniProt Accession Q5Y8C7, O00559, Q6R3F1, E9PND3, E9PN10, E9PJ40, E9PJ38
Search EB-eye ENSG00000147654
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (39 experiments)

Factor Value U/D Experiments
SW480
4
E-MEXP-1014, E-GEOD-18005, E-MTAB-37, E-GEOD-2509
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
BT474
2
E-MEXP-440, E-MTAB-62
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
MCF-10A
2
E-GEOD-14990, E-TABM-420
T84
2
E-GEOD-1474, E-MTAB-37
414 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-13909, E-GEOD-13987, E-GEOD-21750, ... (39 experiments)

Factor Value U/D Experiments
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
primary T lymphocytes
1
E-GEOD-13909
LCC
1
E-GEOD-19188
human embryonic stem cell
1
E-GEOD-18147
centroblast
1
E-TABM-702
74 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1577, E-TABM-15, E-GEOD-3678, E-GEOD-20168, ... (56 experiments)

Factor Value U/D Experiments
benign prostatic hyperplasia
2
E-MEXP-2034, E-GEOD-3868
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
multiple myeloma
2
E-MTAB-62, E-GEOD-2113
papillary thyroid carcinoma
2
E-GEOD-3467, E-GEOD-3678
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
rhabdomyosarcoma
2
E-MTAB-37, E-MTAB-62
169 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (26 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
baseline propofol
1
E-GEOD-4386
sevoflurane
1
E-GEOD-4386
unknown
1
E-GEOD-7307
selenium
1
E-MEXP-1327
phorbol 12-myristate 13-acetate + ionomycin
1
E-GEOD-3720
37 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-2191, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-2509, E-TABM-147, E-GEOD-21138, E-GEOD-1751, ... (6 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, ... (7 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-22593, E-TABM-321, E-TABM-868, E-GEOD-18005, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-5681, E-GEOD-20504, E-MEXP-1446, E-GEOD-22278, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-26, ... (36 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-980, E-GEOD-17400, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-18995

Sex
studied in E-GEOD-12293, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.402 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM